Stephen Plantholt, MD
Cardiovascular Disease · Baltimore, MDNPI 1265426274
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 369 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations.
Across 369 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Boehringer Ingelheim$795
- Amgen$545
- E.r. Squibb & Sons, L.L.C.$522
- Esperion Therapeutics, Inc.$426
- Scpharmaceuticals Inc.$410
- plus $4K from 31 others
Across 968 payments — averaging $576.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$251K
- Alnylam Pharmaceuticals Inc.$204K
- Eli Lilly$98K
- Novartis$4K
What the payments were for
- Food & beverage$7,293100%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 70 | $1,048 |
| Boehringer Ingelheim | 37 | $795 |
| Amgen | 23 | $545 |
| E.r. Squibb & Sons, L.L.C. | 22 | $522 |
| Esperion Therapeutics, Inc. | 25 | $426 |
| Scpharmaceuticals Inc. | 14 | $410 |
| Bayer | 14 | $399 |
| Pfizer | 27 | $341 |
| Johnson & Johnson | 26 | $334 |
| Merck | 16 | $295 |
| AstraZeneca | 15 | $283 |
| Medtronic | 3 | $276 |
| Boston Scientific | 3 | $190 |
| Baxter Healthcare | 5 | $175 |
| Novo Nordisk | 8 | $160 |
| Atricure, Inc. | 3 | $112 |
| Abbott | 2 | $111 |
| Amarin Pharma, Inc. | 7 | $110 |
| Lexicon Pharmaceuticals, Inc. | 5 | $106 |
| Daiichi Sankyo Inc. | 3 | $78 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $67 |
| Regeneron Healthcare Solutions, Inc. | 4 | $66 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $57 |
| Lilly USA, LLC | 3 | $51 |
| Gilead | 4 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Philips North America LLC | 2 | $42 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Akcea Therapeutics, Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$150
- WATCHMAN Access System$142
- Kerendia$137
- FUROSCIX$121
- ONYX FRONTIER$114
How this compares
$7,326 in reported general payments places this provider in the 75th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 419 | $352,636 |
| EliquisApixaban | 310 | $333,896 |
| EntrestoSacubitril/Valsartan | 265 | $313,824 |
| XareltoRivaroxaban | 115 | $121,458 |
| FarxigaDapagliflozin Propanediol | 74 | $74,851 |
| Repatha SureclickEvolocumab | 45 | $60,244 |
| BrilintaTicagrelor | 26 | $18,795 |
| Praluent PenAlirocumab | 17 | $16,524 |
| NexlizetBempedoic Acid/Ezetimibe | 18 | $12,413 |
| Metoprolol Succinate | 613 | $10,251 |
| Atorvastatin Calcium | 481 | $8,146 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 150 | $6,589 |
| Valsartan | 128 | $5,012 |
| VascepaIcosapent Ethyl | 18 | $4,131 |
| Rosuvastatin Calcium | 105 | $3,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $795 | $352,636419 claims |
| PfizerEliquis | $341 | $333,896310 claims |
| NovartisEntresto | $1,048 | $313,824265 claims |
| Johnson & JohnsonXarelto | $334 | $121,458115 claims |
| AstraZenecaFarxiga, Brilinta | $283 | $93,646100 claims |
| Esperion Therapeutics, Inc.Nexlizet | $426 | $12,41318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Baltimore
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Charles CummingsBaltimore$114K
- John RickardBaltimore$109K
- Christopher DefilippiBaltimore$101K
- David KassBaltimore$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.